Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 and AK117 With or Without Chemotherapy in Advanced Malignant Tumors
NCT05235542Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab and ligufalimab in solid tumor, gastric cancer (GC), gastroesophageal junction cancer and 1 more (5 arms), sponsored by Akeso, Inc. Primary endpoints: Number of patients with Adverse Events and Objective Response Rate. Started Mar 2022; status: completed.
02
Drugs
cadonilimabligufalimab
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction cancerEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05235542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235542.